Department of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
BMJ Open. 2021 Nov 25;11(11):e054160. doi: 10.1136/bmjopen-2021-054160.
70%-84% of individuals with antipsychotic treatment resistance show non-response from the first episode. Emerging cross-sectional evidence comparing cognitive profiles in treatment resistant schizophrenia to treatment-responsive schizophrenia has indicated that verbal memory and language functions may be more impaired in treatment resistance. We sought to confirm this finding by comparing cognitive performance between antipsychotic non-responders (NR) and responders (R) using a brief cognitive battery for schizophrenia, with a primary focus on verbal tasks compared against other measures of cognition.
Cross-sectional.
This cross-sectional study recruited antipsychotic treatment R and antipsychotic NR across four UK sites. Cognitive performance was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS).
One hundred and six participants aged 18-65 years with a diagnosis of schizophrenia or schizophreniform disorder were recruited according to their treatment response, with 52 NR and 54 R cases.
Composite and subscale scores of cognitive performance on the BACS. Group (R vs NR) differences in cognitive scores were investigated using univariable and multivariable linear regressions adjusted for age, gender and illness duration.
Univariable regression models observed no significant differences between R and NR groups on any measure of the BACS, including verbal memory (ß=-1.99, 95% CI -6.63 to 2.66, p=0.398) and verbal fluency (ß=1.23, 95% CI -2.46 to 4.91, p=0.510). This pattern of findings was consistent in multivariable models.
The lack of group difference in cognition in our sample is likely due to a lack of clinical distinction between our groups. Future investigations should aim to use machine learning methods using longitudinal first episode samples to identify responder subtypes within schizophrenia, and how cognitive factors may interact within this.
REC: 15/LO/0038.
70%-84%的抗精神病药物治疗抵抗个体在首次发作时表现出无反应。正在出现的比较治疗抵抗性精神分裂症和治疗反应性精神分裂症认知特征的横断面证据表明,言语记忆和语言功能在治疗抵抗中可能受损更严重。我们试图通过使用简短的精神分裂症认知测试来比较抗精神病药物无反应者(NR)和反应者(R)的认知表现来证实这一发现,主要关注言语任务与其他认知测量的比较。
横断面研究。
这项横断面研究在英国的四个地点招募了抗精神病药物治疗的 R 和 NR 患者。使用简短的精神分裂症认知评估(BACS)评估认知表现。
根据他们的治疗反应,招募了 106 名年龄在 18-65 岁之间、被诊断为精神分裂症或分裂样障碍的患者,其中 52 名 NR 和 54 名 R 病例。
BACS 的认知表现的综合和子量表得分。使用单变量和多变量线性回归,根据年龄、性别和疾病持续时间调整,研究了 R 和 NR 组之间认知得分的差异。
单变量回归模型观察到 R 和 NR 组之间在 BACS 的任何测量上都没有显著差异,包括言语记忆(ß=-1.99,95%CI-6.63 至 2.66,p=0.398)和言语流畅性(ß=1.23,95%CI-2.46 至 4.91,p=0.510)。这种发现模式在多变量模型中是一致的。
我们样本中认知无组间差异可能是由于我们组之间的临床区别不大。未来的研究应旨在使用机器学习方法对首发样本进行纵向研究,以确定精神分裂症中的反应者亚型,以及认知因素如何在其中相互作用。
REC:15/LO/0038。